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ABSTRACT
Background: Virus infection is an important risk factor for aggravation of childhood asthma. The objective of
this study was to examine the effect of drugs on aggravation of asthma induced by a common cold.
Methods: Asthma control was examined in a survey of 1,014 Japanese pediatric patients with bronchial
asthma. The occurrence of common cold, asthma control, and drugs used for asthma control were investigated
using a modified Childhood Asthma Control Test (C-ACT) for patients aged <4 years old and 4 to 11 years old,
and an Asthma Control Test (ACT) for patients aged 12 to 15 years old.
Results: The status of asthma control did not differ among the age groups. The prevalence of common cold
and aggravation of asthma were significantly higher in patients aged <4 years old. Control of asthma following
common cold-induced aggravation was significantly less effective in patients aged <4 years old compared to
those aged 4 years old. In patients aged <4 years old with a common cold, asthma control was significantly
more effective for those treated with leukotriene receptor antagonists (LTRAs) compared to treatment without
LTRAs. Asthma control did not differ between patients who did or did not take inhaled corticosteroids or long-
acting β2 stimulants.
Conclusions: These findings showed a high prevalence of common cold in younger patients with childhood
asthma and indicated that common cold can induce aggravation of asthma. LTRAs are useful for long-term
asthma control in very young patients who develop an asthma attack due to a common cold.
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INTRODUCTION
The basic pathology of childhood asthma is persis-
tent inflammation of the respiratory tract. Respiratory
tract infection is an important factor in development
and aggravation of asthma, and respiratory syncytial
(RS) virus,1 rhinovirus2 and metapneumovirus3 infec-
tions are important in young patients. Aggravation of
asthma by viruses involves respiratory epithelium in-
jury4 caused by direct stimulation of the respiratory
tract by viral infection and increased airway hyper-
sensitivity accompanying aggravation of respiratory
tract inflammation.5 Therefore, inhibition of airway in-
flammation using drugs for long-term control such as
inhaled corticosteroids (ICS), leukotriene receptor
antagonists (LTRAs), and suplatast (a Th2 cytokine
inhibitor) and early use of allergen-specific immuno-
therapy may have preventive and inhibitory effects on
aggravation of asthma.
ICS for long-term control of asthma were first rec-
ommended in 2008,6 but a preventive effect of ICS in
the early phase of asthma development in children
has not been proven in large-scale clinical trials.7-9 In
contrast, Bisgaard et al.10 reported that early use of a
LTRA, montelukast, significantly inhibited aggrava-
tion of asthma in children. Early use of LTRAs as oral
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antiinflammatory agents is also likely to have a secon-
dary preventive effect. Suplatast can also inhibit
asthma development in children with an atopic dispo-
sition.11
There are few studies on the effects of drugs for
long-term control of pediatric asthma aggravated by a
common cold. For appropriate treatment of such
cases, it is important to determine the status of con-
trol and the drugs used for long-term control. There-
fore, the aim of this study was to examine whether
ICS, LTRAs and other drugs inhibit common cold-
induced aggravation of childhood asthma, based on a
survey of patients in Tochigi Prefecture.
METHODS
The subjects were childhood asthma patients who
visited 59 pediatric clinics and hospitals in Tochigi
Prefecture from August 1 to November 30, 2008. In a
questionnaire survey, the patients or their parents
were asked about the prevalences of common cold
and common cold-induced aggravation of asthma,
and the status of asthma control for the previous 4
weeks. Physicians provided information on the pa-
tient background and the drugs used by the patients.
Long-acting β2 stimulant was defined as tulobuterol
patch, which is approved as a transdermal β2 stimu-
lant in Japan and has an effect similar to that of sal-
meterol.12 Tulobuterol is widely used and is recom-
mended for long-term asthma control in the same
manner as a long-acting inhaled β2 stimulant in the
Japanese Pediatric Guideline for the Treatment and
Management of Asthma 2005 (JPGL 2005).6 Suplatast
is a Th2 cytokine inhibitor that is approved as an anti-
inflammatory drug and is available only in Japan. In
this study, we confirmed good patient compliance
orally or using a diary.
The classification of atopy and non-atopy was de-
fined by a physician depending on the presence of
predisposing factors for atopic disease (a family his-
tory of atopy, a history of allergic disease, or a predis-
position to IgE production). During the study period,
patients who developed symptoms such as nasal dis-
charge, cough, and sore throat with no fine crackles
detected through chest auscultation were diagnosed
with a common cold. Patients with other acute symp-
toms andor chronic respiratory diseases (e.g. cystic
fibrosis, bronchopulmonary dysplasia, and primary
dyskinesia) were excluded from this diagnosis.
Asthma severity was classified into intermittent, mild
persistent, moderate persistent, and severe persistent
types according to the JPGL 2005 criteria.6 Asthma
control was evaluated using a modified version of the
Childhood Asthma Control Test (C-ACT) and the
Asthma Control Test (ACT). In the original C-ACT,
cases scoring20 points are classified as “Controlled”
or “Partly Controlled” and those with <20 points as
“Uncontrolled”. In the modified C-ACT, cases with 26
or 27 points were classified as “Controlled”, those
with 20 to 25 points as “Partly Controlled”, and those
with <20 points as “Uncontrolled”. The modified C-
ACT was used for patients aged 11 years old. The
questionnaire was completed by parents for patients
aged <4 years old and by the patient or their parents
for patients aged 4 to 11 years old. Patients aged 12 to
15 years old completed the ACT by themselves. In
the ACT, cases with a full score (25 points) were con-
sidered to be “Controlled”, those with 20 to 24 points
were “Partly Controlled”, and those with <20 points
were “Uncontrolled”.13
This study was approved by the Regional Ethics
Committee for Human Research at Dokkyo Medical
University Hospital. The parents of all patients partici-
pating in this study gave oral and written informed
consent.
Comparison of the prevalences of common cold
and common cold-induced aggravation of asthma,
and the drugs used for asthma control between age
groups was performed by χ2 test. The status of
asthma control and the drugs used for patients aged
<4 years old with a common cold were analyzed by
Mann-Whitney U test. A p value <0.05 was considered
to indicate a significant difference.
RESULTS
PATIENT BACKGROUND
Data were collected from 1,047 pediatric patients and
1,014 data were used to the analysis. 33 patients were
excluded from the analysis because the ages were
more than 16 years or the background data such as
age and sex were not obtained. The mean age (± SD)
was 6.3 ± 3.3 years old and a male: female ratio was
62.2%: 37.8%. The periods of time the children spent
with their parents each day were <8 hours, 8 to 12
hours, 12 to 24 hours, and unknown for 15.6%, 26.9%,
40.4% and 17.1% of the patients, respectively. Asthma
was classified as atopic, non-atopic, and unknown in
73.7%, 22.0% and 4.3% of the patients, respectively,
and the severity of the disease was intermittent, mild
persistent, moderate persistent, severe persistent,
and unknown in 18.4%, 50.0%, 23.8%, 1.6% and 6.2%, re-
spectively. The drugs used for long-term control
either alone or concomitantly included theophylline
(oral), DSCG, oral antiallergic agents, LTRAs, long-
acting β2 stimulants, ICS, and suplatast in 8.4%, 11.3%,
19.4%, 83.2%, 11.6%, 49.5% and 4.6% of the patients, re-
spectively (Table 1).
ASTHMA CONTROL
Evaluations using the modified C-ACT or ACT indi-
cated that asthma control was similar in the age
groups of <4, 4 to 11, and 12 to 15 years old. The per-
centage of controlled, partly controlled and uncon-
trolled cases among patients aged <4 years old were
42.7%, 40.4% and 11.6%, respectively. These respective
rates were 39.8%, 40.4% and 8.8% in patients aged 4 to
11 years old; and 44.4%, 35.8% and 12.3% in those aged
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Table　1　Patient background
<4
years old
n = 225
4-11
years old
n = 708
12-15
years old
n = 81
Overall
n = 1014
Sex Male 155 (68.9) 427 (60.3) 49 (60.5) 631 (62.2)
Female 70 (31.1) 281 (39.7) 32 (39.5) 383 (37.8)
Respondent Mother 198 (88.0) 622 (87.9) 69 (85.2) 889 (87.7)
Father 9 (4.0) 28 (4.0) 5 (6.2) 42 (4.1)
Grandfather 0 (0.0) 3 (0.4) 0 (0.0) 3 (0.3)
Grandmother 2 (0.9) 17 (2.4) 1 (1.2) 20 (2.0)
Others/Unknown 12 (5.3) 23 (3.2) 3 (3.7) 38 (3.7)
No answer 4 (1.8) 15 (2.1) 3 (3.7) 22 (2.2)
Contact duration <8 hours 26 (11.6) 106 (15.0) 26 (32.1) 158 (15.6)
8-12 hours 40 (17.8) 203 (28.7) 30 (37.0) 273 (26.9)
12-24 hours 116 (51.6) 281 (39.7) 13 (16.0) 410 (40.4)
No answer 43 (19.1) 118 (16.7) 12 (14.8) 173 (17.1)
Disease type Atopic 146 (64.9) 534 (75.4) 67 (82.7) 747 (73.7)
Non-atopic 70 (31.1) 140 (19.8) 13 (16.0) 223 (22.0)
No answer 9 (4.0) 34 (4.8) 1 (1.2) 44 (4.3)
Severity Intermittent 32 (14.2) 143 (20.2) 12 (14.8) 187 (18.4)
Mild persistent 114 (50.7) 355 (50.1) 38 (46.9) 507 (50.0)
Moderate persistent 66 (29.3) 154 (21.8) 21 (25.9) 241 (23.8)
Severe persistent 4 (1.8) 8 (1.1) 4 (4.9) 16 (1.6)
Unknown 9 (4.0) 48 (6.8) 6 (7.4) 63 (6.2)
Drug for long-term control Theophylline (oral) 8 (3.6) 64 (9.0) 13 (16.0) 85 (8.4)
DSCG 33 (14.7) 76 (10.7) 6 (7.4) 115 (11.3)
Oral antiallergic drug 33 (14.7) 142 (20.1) 22 (27.2) 197 (19.4)
LTRA 202 (89.8) 583 (82.3) 59 (72.8) 844 (83.2)
Long-acting β2 stimulant 39 (17.3) 75 (10.6) 4 (4.9) 118 (11.6)
ICS 111 (49.3) 347 (49.0) 44 (54.3) 502 (49.5)
Suplatast† (Th2 cytokine inhibitor) 7 (3.1) 32 (4.5) 8 (9.9) 47 (4.6)
Percentages are shown in parentheses. †Suplatast is available only in Japan.
Table　2　Status of asthma control among the patients
Asthma Control
<4
years old
n = 225
4-11
years old
n = 708
12-15
years old
n = 81
Controlled 96 (42.7) 282 (39.8) 36 (44.4)
Partly Controlled 91 (40.4) 285 (40.4) 29 (35.8)
Uncontrolled 26 (11.6) 62 (8.8) 10 (12.3)
Unknown 12 (5.3) 78 (11.0) 6 (7.4)
Asthma control was evaluated using the modifi ed C-ACT and 
ACT questionnaires. For  patients <4 years old, parents completed 
the modifi ed C-ACT. For patients aged 4 to 11 years old, the pa-
tients or their parents completed the modifi ed C-ACT. Patients 
aged 12 to 15 years old fi lled in the ACT themselves.
On the modifi ed C-ACT, 26 or 27 points was considered to indi-
cate asthma that was controlled, 20 to 25 points indicated partly
controlled, and <20 points indicated uncontrolled.
On the ACT, 25 points indicated controlled, 20 to 24 points indi-
cated controlled, and <20 points indicated uncontrolled.
Percentages are shown in parentheses.
12 to 15 years old (Table 2).
PREVALENCES OF COMMON COLD AND ASTH-
MA AGGRAVATED BY COMMON COLD
Among all patients, 46.4% had developed a common
cold in the 4 weeks before completion of the survey.
These rates were 62.2%, 43.1% and 30.9% in the <4, 4
to 11, and 12 to 15 age groups, respectively, with a
significantly higher incidence in patients aged <4
years old (p < 0.001). Aggravation of asthma by the
common cold occurred in 34.0% of all patients, and in
49.3%, 28.2% and 24.0% in the <4, 4 to 11, and 12 to 15
age groups, respectively. This incidence was also sig-
nificantly higher in patients aged <4 years old (p <
0.001) (Table 3).
ASTHMA CONTROL, COMMON COLD, AND
ASTHMA AGGRAVATION IN PATIENTS AGED <4
YEARS OLD
Asthma control in patients aged <4 years old with a
common cold was significantly poorer than that in pa-
tients in the same age group without a common cold
Yoshihara S et al.
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Fig.　1　Effects of drugs for asthma control in asthma patients <4 years old with a com-
mon cold. The black, striped, white and dotted bars show cases that were uncontrolled, 
partly controlled, controlled, and not determined, respectively. *p < 0.05. Other information 
is given in the footnote to Table 4.
0%
LTRA (-)
(n = 11)
LTRA (+)
(n = 129)
ICS (-)
(n = 75)
ICS (+)
(n = 65)
Long-acting β2 stimulant (-)
(n = 114)
Long-acting β2 stimulant (+)
(n = 26)
50% 100%
*
0% 50% 100%
0% 50% 100%
Table　3　Incidences of common cold and asthma aggravated by common cold over 4 weeks
<4
years old
n = 225
4-11
years old
n = 708
12-15
years old
n = 81
Overall
n = 1014
p value
<4 vs 4-11
years old
<4 vs 12-15
years old
12-15 vs 4-11
years old
Common cold 140 (62.2) 305 (43.1) 25 (30.9) 470 (46.4) <0.001 <0.001 <0.05
Aggravated asthma  69 (49.3)  86 (28.2)  6 (24.0) 161 (34.0) <0.001 <0.001 N.S.
Percentages are shown in parentheses. N.S., not signifi cantly different.
Table　4　Incidences of common cold and asthma aggravated by common cold and status of asthma control in patients aged 
younger than 4 years old
Controlled PartlyControlled Uncontrolled
p value
Controlled vs 
Partly Controlled
Controlled vs 
Uncontrolled
Partly Controlled vs 
Uncontrolled
Common cold 41/96 (42.7) 67/91 (73.6) 24/26 (92.3) <0.001 <0.001 <0.05
Asthma aggravated 
by common cold  2/41 (4.8) 39/69 (56.5) 22/24 (91.6) <0.001 <0.001 <0.01
Asthma control was evaluated using the modifi ed C-ACT questionnaire, which was completed by parents.
On the modifi ed C-ACT, 26 or 27 points was considered to indicate asthma that was controlled, 20 to 25 points indicated partly controlled, 
and <20 points indicated uncontrolled.
Percentages are shown in parentheses.
(p < 0.001). Control of asthma aggravated by a com-
mon cold in patients aged <4 years old was also sig-
nificantly poorer than that in patients in the same age
group with no aggravation of asthma (p < 0.001) (Ta-
ble 4).
ASTHMA CONTROL AND DRUGS USED IN PA-
TIENTS AGED <4 YEARS OLD WITH A COMMON
COLD
The effects of LTRAs, ICS, and long-acting β2 stimu-
lants, all of which were used at high rates, on asthma
control were examined in patients aged <4 years old
with a common cold. Asthma control in this age
group was significantly better for patients treated
with LTRAs compared with those who did not receive
LTRAs (p < 0.05). In contrast, no significant differ-
ence in asthma control was found for patients aged <4
years old who did or did not receive ICS or long-
acting β2 stimulants (Fig. 1).
Treatment of Common Cold-Induced Asthma
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DISCUSSION
Respiratory infection is an important factor in devel-
opment and aggravation of pediatric bronchial
asthma. The mechanism is thought to involve an in-
crease in airway hypersensitivity accompanied with
airway epithelium injury and inflammation aggra-
vated by direct stimulation by virus infection.5 Drugs
for long-term control such as LTRAs, ICS and long-
acting β2 stimulants are used clinically, but the ef-
fects of these drugs on asthma aggravated by a com-
mon cold have not been widely examined.
We performed a survey of asthma control in pa-
tients with childhood asthma at multiple medical fa-
cilities in Tochigi Prefecture to examine whether
drugs for long-term control inhibited aggravation of
asthma caused by virus infection. The prevalences of
common cold and asthma aggravated by common
cold were particularly high in younger patients (<4
years old). Asthma symptoms caused by rhinovirus
and RS virus infection are especially common in in-
fants, and RS virus infection has been related to suc-
cessive development of asthma and increased airway
hypersensitivity.1,2,14 Lung Mycoplasma pneumoniae
and Chlamydia pneumoniae cause acute chronic
wheezing.15 The airway internal diameter is smaller
and lung elastic recoil is decreased in infants com-
pared to older children, and thus airway narrowing
may easily develop and lead to rapid progression of
symptoms.16 Therefore, it is important to examine
whether early use of drugs for long-term control in in-
fants can inhibit progression of asthma.
We evaluated the effects of drugs on asthma con-
trol in children using a modified C-ACT, which in-
cluded two modifications to the original C-ACT. The
first was to consider patients with 26 points on the
C-ACT to be “Controlled”. In development and valida-
tion of the C-ACT, Liu et al. compared C-ACT scores
by dividing 257 pediatric asthma patients using pa-
rameters for respiratory function and asthma con-
trol.17 The favorable groups had %FEV1 100%,
FEV1FVC 100%, a “step down” change in therapy,
and completely controlled asthma based on assess-
ment by a specialist. The C-ACT scores for these
groups were 20.19 ± 4.11, 20.14 ± 3.98, 20.08 ± 4.41,
and 22.27 ± 3.28, respectively. Therefore, patients
with26 points (higher than the mean +1 SD for each
group) should have very favorable asthma control.
The second modification of the C-ACT was made
for evaluation of the current status of asthma control
in patients aged <4 years old. Parents of these pa-
tients were asked to answer all the questions on the
modified C-ACT, but two difficulties were encoun-
tered in this approach: it was unclear whether the
modified C-ACT score reflected objective asthma
symptoms in patients aged <4 years old; and whether
the answers given by the parents overestimated or
underestimated the asthma symptoms in these pa-
tients. With regard to the validity of the C-ACT score,
Yoshihara et al. reported that nocturnal sleep disor-
der in parents of infant asthma patients had a positive
correlation with asthma symptoms in the patients.18
In an investigation of the relationship of the modified
C-ACT score with nocturnal sleep disorder in parents
induced by an asthmatic attack in the pediatric pa-
tients, we found a positive correlation between the
modified C-ACT score and nocturnal sleep disorder
for parents of pediatric asthma patients aged <4 years
old and aged 4-11 years old (data not shown). This
suggests that the modified C-ACT score does reflect
asthma symptoms in all pediatric patients. Regarding
the accuracy of parent answers, we asked ten pediat-
ric patients aged 4-11 years old and their parents to
answer questions Q1 to Q4 independently, and calcu-
lated the modified C-ACT scores. There was no sig-
nificant difference in C-ACT score between the pa-
tients and their parents (data not shown). These find-
ings suggest that an effective evaluation of the cur-
rent status of asthma control in patients aged <4
years old can be obtained using the modified C-ACT
score.
The effects of LTRAs, ICS, and long-acting β2
stimulants on control of pediatric asthma in patients
aged <4 years old with a common cold were exam-
ined using the modified C-ACT. Asthma control in
these patients was significantly better in those who
received LTRAs compared to those that did not take
these drugs. In contrast, use of ICS and long-acting
β2 stimulants did not result in a significant improve-
ment in asthma control compared to patients who did
not take the respective drugs. These results suggest
that LTRAs inhibit common cold-induced aggravation
of asthma in younger children and give favorable
asthma control. A secondary preventive effect of ICS
in the early phase of asthma development was not
found in large-scale trials,7-9 whereas Bisgaard et al.
found that early use of montelukast in patients aged 2
to 5 years old with mild intermittent asthma signifi-
cantly inhibited asthma aggravation.10 These results
suggest that LTRAs inhibit common cold-induced ag-
gravation of asthma in younger children and give fa-
vorable asthma control, but require confirmation in a
prospective comparative study.
LTRAs are oral drugs with high tolerability that can
reach the peripheral airway via the blood, and are
widely used in treatment of childhood asthma. Our
results suggest that LTRAs can contribute to control
of an asthma attack accompanied by a common cold.
The prevalences of common cold and acute aggrava-
tion of childhood asthma by a common cold were par-
ticularly high in younger patients (<4 years old), and
asthma control in these patients was poor. LTRAs
may be particularly useful for long-term control and
inhibition of common cold-induced aggravation of
asthma in these patients.
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